Voriconazole prophylaxis in children with cancer: Changing outcomes and epidemiology of fungal infections

Pediatric Infectious Disease Journal

Volumn 32, Issue 12, 2013, Pages

  Maron, Gabriela M ^a   Hayden, Randall T ^a   Rodriguez, Alicia ^a   Rubnitz, Jeffrey E ^a   Flynn, Patricia M ^a   Shenep, Jerry L ^a   Knapp, Katherine M ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Aspergillus; Pediatric; Prophylaxis; Voriconazole

Indexed keywords

AMPHOTERICIN B; ANTINEOPLASTIC AGENT; ECHINOCANDIN; GALACTOMANNAN; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ANTIBIOTIC PROPHYLAXIS; ANTIFUNGAL PROPHYLAXIS; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS TERREUS; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD CANCER; DISEASE PREDISPOSITION; DRUG USE; ETHMOIDECTOMY; FEMALE; FUSARIUM OXYSPORUM; HUMAN; LUNG INFECTION; MACROPHOMINA PHASEOLINA; MAJOR CLINICAL STUDY; MALE; MYCOSIS; NEUTROPENIA; NEUTROPHIL COUNT; NONHUMAN; PHAEOHYPHOMYCOSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SKIN; SOFT TISSUE INFECTION; SURVIVAL; TREATMENT OUTCOME; WEDGE RESECTION; YOUNG ADULT; ZYGOMYCOSIS; CLINICAL TRIAL; INFANT; LEUKEMIA, MYELOID, ACUTE; MICROBIOLOGY; MULTICENTER STUDY; MYCOSES;

ADOLESCENT; ADULT; ANTIBIOTIC PROPHYLAXIS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; LEUKEMIA, MYELOID, ACUTE; MALE; MYCOSES; TREATMENT OUTCOME; VORICONAZOLE; YOUNG ADULT;

EID: 84891746294     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3182a74233     Document Type: Article

References (36)

1. Cornely OA, Böhme A, Reichert D, et al.; Multinational case registry of the infectious diseases working party of the German society for hematology and oncology. risk factors for breakthrough invasive fungal infection during secondary prophylaxis. J Antimicrob Chemother. 2008;61:939-946.
2. Sung L, Gamis A, Alonzo TA, et al. Infections and association with different intensity of chemotherapy in children with acute myeloid leukemia. Cancer. 2009;115:1100-1108.
3. Burgos A, Zaoutis TE, Dvorak CC, et al. Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics. 2008;121:e1286-e1294.
4. Husain S, Paterson DL, Studer S, et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant. 2006;6:3008-3016.
5. Mattiuzzi GN, Cortes J, Alvarado G, et al. Effcacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Support Care Cancer. 2011;19:19-26.
6. Torres A, Serrano J, Rojas R, et al. Voriconazole as primary antifungal prophylaxis in patients with neutropenia after hematopoietic stem cell transplantation or chemotherapy for acute myeloid leukemia. Eur J Haematol. 2010;84:271-273.
7. Triflio S, Singhal S, Williams S, et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant. 2007;40:451-456.
8. Vehreschild JJ, Böhme A, Buchheidt D, et al. A double-blind trial on prophylactic voriconazole (VrC) or placebo during induction chemotherapy for acute myelogenous leukaemia (aMl). J Infect. 2007;55:445-449.
9. Wingard JR, Carter SL, Walsh TJ, et al.; Blood and marrow transplant clinical trials network. Randomized, double-blind trial of fuconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood. 2010;116:5111-5118.
10. Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the aMl02 multicentre trial. Lancet Oncol. 2010;11:543-552.
11. Rubnitz JE, Crews KR, Pounds S, et al. Combination of cladribine and cyta-rabine is effective for childhood acute myeloid leukemia: results of the St Jude aMl97 trial. Leukemia. 2009;23:1410-1416.
12. De PB, Walsh TJ, Donnelly JP, et al. Revised defnitions of invasive fungal disease from the european Organization for research and treatment of Cancer/invasive Fungal infections Cooperative group and the national institute of allergy and infectious diseases Mycoses Study group (eOrtC/MSg) Consensus group. Clin Infect Dis. 2008;46:1813-1821.
13. Segal BH, Herbrecht R, Stevens DA, et al. Defning responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study group and european Organization for research and treatment of Cancer consensus criteria. Clin Infect Dis. 2008;47:674-683.
14. Mandhaniya S, Swaroop C, Thulkar S, et al. Oral voriconazole versus intravenous low dose amphotericin B for primary antifungal prophylaxis in pedi-atric acute leukemia induction: a prospective, randomized, clinical study. J Pediatr Hematol Oncol. 2011;33:e333-e341.
15. Molina JR, Serrano J, Sánchez-García J, et al. Voriconazole as primary antifungal prophylaxis in children undergoing allo-SCt. Bone Marrow Transplant. 2012;47:562-567.
16. Abbasi S, Shenep JL, Hughes WT, et al. Aspergillosis in children with cancer: a 34-year experience. Clin Infect Dis. 1999;29:1210-1219.
17. Ben-AMI R, Lewis RE, Raad II, et al. Phaeohyphomycosis in a tertiary care cancer center. Clin Infect Dis. 2009;48:1033-1041.
18. Husain S, Alexander BD, Munoz P, et al. Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-aspergillus mycelial fungi. Clin Infect Dis. 2003;37:221-229.
19. Siwek GT, Pfaller MA, Polgreen PM, et al. Incidence of invasive aspergil-losis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis. Diagn Microbiol Infect Dis. 2006;55:209-212.
20. Imhof A, Balajee SA, Fredricks DN, et al. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis. 2004;39:743-746.
21. Triflio SM, Bennett CL, Yarnold PR, et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant. 2007;39:425-429.
22. Lamaris GA, Ben-Ami R, Lewis RE, et al. Increased virulence of Zygomycetes organisms following exposure to voriconazole: a study involving fy and murine models of zygomycosis. J Infect Dis. 2009;199: 1399-1406.
23. Tortorano AM, Esposto MC, Prigitano A, et al. Cross-reactivity of Fusarium spp. in the aspergillus galactomannan enzyme-linked immunosorbent assay. J Clin Microbiol. 2012;50:1051-1053.
24. Cornely OA, Vehreschild JJ, Rüping MJ. Current experience in treating invasive zygomycosis with posaconazole. Clin Microbiol Infect. 2009;15(suppl 5):77-81.
25. Langner S, Staber PB, Neumeister P. Posaconazole in the management of refractory invasive fungal infections. Ther Clin Risk Manag. 2008;4: 747-758.
26. Lehrnbecher T, Attarbaschi A, Duerken M, et al. Posaconazole salvage treatment in paediatric patients: a multicentre survey. Eur J Clin Microbiol Infect Dis. 2010;29:1043-1045.
27. Herbrecht R, Denning DW, Patterson TF, et al.; Invasive fungal infections group of the european organisation for research and treatment of cancer and the global aspergillus study group. Voriconazole versus ampho-tericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408-415.
28. Neofytos D, Horn D, Anaissie E, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective antifungal therapy (PatH) alliance registry. Clin Infect Dis. 2009;48:265-273.
29. Wingard JR, Herbrecht R, Mauskopf J, et al. Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive asper-gillosis. Transpl Infect Dis. 2007;9:182-188.
30. Jeu L, Piacenti FJ, Lyakhovetskiy AG, et al. Voriconazole. Clin Ther. 2003;25:1321-1381.
31. Pfzer INC. VFend uS Physician Prescribing information. 2013. available at: http://www.pfzer.com/products/product-detail/vfend. accessed July 13, 2013.
32. US Food and drug administration. FDA approved drug Products. available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index. cfm?fuseaction=Search.drugdetails. accessed July 13, 2013.
33. Walsh TJ, Anaissie EJ, Denning DW, et al.; Infectious diseases society of America. Treatment of aspergillosis: clinical practice guidelines of the infectious diseases Society of america. Clin Infect Dis. 2008;46:327-360.
34. Shima H, Miharu M, Osumi T, et al. Differences in voriconazole trough plasma concentrations per oral dosages between children younger and older than 3 years of age. Pediatr Blood Cancer. 2010;54:1050-1052.
35. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fucona-zole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356:335-347.
36. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fuconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356:348-359.